Mendel.ai

Mendel.ai

A life science company offering an artificial intelligence platform to aid clinical experts improve their clinical cancer research.

Mendel.ai is a life science company offering an artificial intelligence platform to aid clinical experts improve their clinical cancer research that is headquartered in San Jose, California and was founded in 2016 by Karim Galil, Ruchi Deshpande, and Wael Salloum. The AI platform is named "Mendel Brain" and is made to aid clinicians in all aspects of clinical trial research. The company claims Mendel Brain allows querying of medical records, skimming through scientific papers, help with feasibility surveys, and augmenting screening processes.

Funding

Convertible note

On November 2, 2016 Mendel.ai announced receiving a convertible note from SOSV and IndieBio for an undisclosed amount.

Seed

On July 1, 2017 Mendel.ai announced raising $2 million in funding from DCM Ventures, Bootstrap Labs, and Launch Capital. The company plans on using their seed funding to begin implementing their Mendel Brain product in hospitals and cancer genomics companies. At the time of announcing their seed funding, Mendel.ai began working with the Comprehensive Blood & Cancer Center (CBCC) in Bakersfield, California to help the center match patients with doctors and clinical trials for treating cancer.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Mendel.ai funding round, July 2017
2,000,000
July 2017
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Abdulaziz Alaa

Employee

Ashkon Zariv

Employee

Bernal Jimenez

Employee

Karim Galil

Founder

Karim Galil

Past investor

Mark H Goldstein

Past investor

Mark H Goldstein

Advisor

Ruchi Deshpande

Founder

Sherry Karam

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.